TWI794885B - 全身紅斑性狼瘡之治療 - Google Patents

全身紅斑性狼瘡之治療 Download PDF

Info

Publication number
TWI794885B
TWI794885B TW110125851A TW110125851A TWI794885B TW I794885 B TWI794885 B TW I794885B TW 110125851 A TW110125851 A TW 110125851A TW 110125851 A TW110125851 A TW 110125851A TW I794885 B TWI794885 B TW I794885B
Authority
TW
Taiwan
Prior art keywords
compound
biomarker
sle
sample
biomarkers
Prior art date
Application number
TW110125851A
Other languages
English (en)
Chinese (zh)
Other versions
TW202216156A (zh
Inventor
彼得 H 沙佛
雷 吳
瑩 葉
Original Assignee
美商西建公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司 filed Critical 美商西建公司
Publication of TW202216156A publication Critical patent/TW202216156A/zh
Application granted granted Critical
Publication of TWI794885B publication Critical patent/TWI794885B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW110125851A 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療 TWI794885B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462000428P 2014-05-19 2014-05-19
US62/000,428 2014-05-19
US201462053626P 2014-09-22 2014-09-22
US62/053,626 2014-09-22

Publications (2)

Publication Number Publication Date
TW202216156A TW202216156A (zh) 2022-05-01
TWI794885B true TWI794885B (zh) 2023-03-01

Family

ID=53268937

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110125851A TWI794885B (zh) 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療
TW104115791A TWI745271B (zh) 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW104115791A TWI745271B (zh) 2014-05-19 2015-05-18 全身紅斑性狼瘡之治療

Country Status (6)

Country Link
US (5) US10245266B2 (enExample)
EP (1) EP3145513B1 (enExample)
JP (3) JP2017522270A (enExample)
ES (1) ES2969532T3 (enExample)
TW (2) TWI794885B (enExample)
WO (1) WO2015179276A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2536706T3 (pl) 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
PT2882441T (pt) 2012-08-09 2020-06-29 Celgene Corp Tratamento de doenças associadas à imunidade e inflamatórias
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
ES2969532T3 (es) * 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
CN116234553A (zh) * 2020-10-02 2023-06-06 新基公司 治疗系统性红斑狼疮的方法和作为对疗法临床敏感性的预测指标的生物标志物的用途
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
TW201408298A (zh) * 2012-08-09 2014-03-01 Celgene Corp 免疫相關及發炎疾病之治療

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
ES2243052T3 (es) 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
GB0120441D0 (en) 2001-08-22 2001-10-17 Novartis Forschungsstiftung Model of autoimmune disease and methods for identifying anti autoimmune disease disorders
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2007133725A1 (en) 2006-05-12 2007-11-22 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US20080045485A1 (en) 2006-08-17 2008-02-21 Peter Muir Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture
CN101562977A (zh) 2006-12-15 2009-10-21 艾博特公司 新的二唑化合物
KR101791757B1 (ko) 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
US20100075333A1 (en) 2007-03-30 2010-03-25 Alain Moreau Method of determining the risk of scoliosis
JP5442185B2 (ja) 2007-04-24 2014-03-12 日本メナード化粧品株式会社 感作性物質評価方法
EP2269072B1 (en) 2008-03-31 2017-08-23 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
CN102144163A (zh) 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法
NZ592801A (en) 2008-12-05 2013-08-30 Abbvie Inc Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
PL2536706T3 (pl) 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
EP2544687A1 (en) * 2010-03-12 2013-01-16 Celgene Corporation Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
US20140148350A1 (en) 2010-08-18 2014-05-29 David Spetzler Circulating biomarkers for disease
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
AU2013271378A1 (en) * 2012-06-07 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of Pin1
PT2880447T (pt) * 2012-07-31 2019-08-02 Novartis Ag Marcadores associados à sensibilidade a inibidores de minuto duplo humano 2 (mdm2)
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
ES2969532T3 (es) * 2014-05-19 2024-05-21 Celgene Corp 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004990A2 (en) * 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
TW201408298A (zh) * 2012-08-09 2014-03-01 Celgene Corp 免疫相關及發炎疾病之治療

Also Published As

Publication number Publication date
JP2017522270A (ja) 2017-08-10
US10245266B2 (en) 2019-04-02
ES2969532T3 (es) 2024-05-21
US20170173029A1 (en) 2017-06-22
JP2020143083A (ja) 2020-09-10
JP2022058443A (ja) 2022-04-12
EP3145513B1 (en) 2023-11-15
US20240041894A1 (en) 2024-02-08
US10980812B2 (en) 2021-04-20
US20200360396A1 (en) 2020-11-19
TW202216156A (zh) 2022-05-01
US20190262348A1 (en) 2019-08-29
US11660302B2 (en) 2023-05-30
EP3145513A1 (en) 2017-03-29
TWI745271B (zh) 2021-11-11
TW201622728A (zh) 2016-07-01
US10596179B2 (en) 2020-03-24
WO2015179276A1 (en) 2015-11-26
US20220008427A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
US11660302B2 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
US11524950B2 (en) Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) Treatment of systemic lupus erythematosus
JP2010500283A (ja) チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
TWI907406B (zh) 使用布魯頓氏酪胺酸激酶抑制劑來治療復發型多發性硬化症之方法
TW202345799A (zh) Ｔｙｋ２抑制劑及其用途
KR20260004440A (ko) 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
HK1232801B (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
TW202140005A (zh) 用於治療發炎疾病之新穎藥物
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase